Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.

[1]  Yuxin Yin,et al.  Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. , 2019, European journal of medicinal chemistry.

[2]  Juntuo Zhou,et al.  Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. , 2019, European journal of medicinal chemistry.

[3]  Honglin Li,et al.  Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. , 2019, Bioorganic & medicinal chemistry.

[4]  Keriann M. Backus,et al.  Opportunities and challenges for the development of covalent chemical immunomodulators. , 2019, Bioorganic & medicinal chemistry.

[5]  L. Silvian,et al.  Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens. , 2019, Bioorganic & medicinal chemistry.

[6]  J. Singh,et al.  Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. , 2019, Bioorganic & medicinal chemistry.

[7]  Hyung‐Ok Kim.  Development of BTK inhibitors for the treatment of B-cell malignancies , 2019, Archives of Pharmacal Research.

[8]  Ewgenij Proschak,et al.  Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. , 2018, Journal of medicinal chemistry.

[9]  Xiaodong Ma,et al.  The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC. , 2018, Bioorganic & medicinal chemistry.

[10]  M. Sawa,et al.  Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis. , 2018, Journal of medicinal chemistry.

[11]  Huijun Sun,et al.  Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines. , 2018, Bioorganic & medicinal chemistry.

[12]  Q. You,et al.  Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ. , 2018, Bioorganic & medicinal chemistry.

[13]  Aliya Ibrar,et al.  Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery. , 2018, Bioorganic & medicinal chemistry.

[14]  Yingxia Li,et al.  Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2018, Bioorganic & medicinal chemistry.

[15]  Yuxin Yin,et al.  Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor in vitro and in vivo. , 2018, MedChemComm.

[16]  Adam R. Johnson,et al.  Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. , 2018, Journal of medicinal chemistry.

[17]  M. Sawa,et al.  Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[18]  Jiri Bartek,et al.  Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4 , 2017, Nature.

[19]  Xiaodong Ma,et al.  Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. , 2017, Bioorganic & medicinal chemistry.

[20]  Yuxin Yin,et al.  Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. , 2017, European journal of medicinal chemistry.

[21]  Xiaodong Ma,et al.  Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity. , 2017, Bioorganic & medicinal chemistry.

[22]  Jinyong Peng,et al.  Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. , 2017, European journal of medicinal chemistry.

[23]  M. Dreyling,et al.  Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives , 2017, Expert opinion on investigational drugs.

[24]  W. Wilson,et al.  The landscape of new drugs in lymphoma , 2017, Nature Reviews Clinical Oncology.

[25]  Jinyong Peng,et al.  C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFRT790M mutant. , 2017, Bioorganic & medicinal chemistry.

[26]  Adam R. Johnson,et al.  Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties , 2017, ACS medicinal chemistry letters.

[27]  Theresa Johnson,et al.  Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling , 2017, Molecular Pharmacology.

[28]  N. Gray,et al.  Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. , 2017, ACS medicinal chemistry letters.

[29]  Dongjun Fu,et al.  Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways. , 2017, European journal of medicinal chemistry.

[30]  Huijun Sun,et al.  Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. , 2017, Bioorganic & medicinal chemistry.

[31]  C. I. Smith,et al.  From identification of the BTK kinase to effective management of leukemia , 2016, Oncogene.

[32]  Jinyong Peng,et al.  Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. , 2016, Bioorganic & medicinal chemistry.

[33]  Adam R. Johnson,et al.  Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. , 2016, ACS chemical biology.

[34]  Yanli Wang,et al.  Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis. , 2016, Bioorganic & medicinal chemistry letters.

[35]  Adam R. Johnson,et al.  Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. , 2016, Bioorganic & medicinal chemistry letters.

[36]  Wei Huang,et al.  Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2015, Bioorganic & medicinal chemistry.

[37]  R. Copeland,et al.  Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. , 2015, Bioorganic & medicinal chemistry.

[38]  Wei Huang,et al.  Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors. , 2015, Bioorganic & medicinal chemistry.

[39]  A. Kamal,et al.  Design and synthesis of dithiocarbamate linked β-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability. , 2015, Bioorganic & medicinal chemistry.

[40]  Wei Huang,et al.  Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[41]  Bin Liu,et al.  New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds. , 2015, Bioorganic & medicinal chemistry.

[42]  C. Supuran,et al.  Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action. , 2015, Bioorganic & medicinal chemistry.

[43]  C. Flowers,et al.  New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy , 2015, Expert review of anticancer therapy.

[44]  Yingbo Li,et al.  Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents. , 2015, European journal of medicinal chemistry.

[45]  S. Hymowitz,et al.  Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834. , 2015, Bioorganic & medicinal chemistry letters.

[46]  Z. Ge,et al.  LRD-22, a novel dual dithiocarbamatic acid ester, inhibits Aurora-A kinase and induces apoptosis and cell cycle arrest in HepG2 cells. , 2015, Biochemical and biophysical research communications.

[47]  L. Ysebaert,et al.  Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies , 2014, Current Opinion in Oncology.

[48]  A. Kater,et al.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future , 2014, Oncogene.

[49]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.